Aclaris stock soars for second day on licensing deal, analyst upgrades
Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...
Pharmaceutical Technology12h
Aclaris Therapeutics secures global rights to Biosion’s antibodies
Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.
Yahoo Finance13h
Concerto Biosciences Announces First Participant Dosed with Live Biotherapeutic ENS-002 in Phase 1 Trial for Atopic Dermatitis
aureus, a core microbial driver of atopic dermatitis, offering a potential novel avenue for treatment. "We are thrilled to have our first participant enrolled," said Chief Executive Officer Cheri ...
Doctor debunks four common eczema myths which are untrue
Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...
Business Insider15h
Eli Lilly Canada ‘disappointed’ by CDA-AMC’s Final Recommendation for Ebglyss
The CDA-AMC recommended that Ebglyss not be reimbursed by public drug plans, excluding Quebec, for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and ...